By Fineline Cube 
German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their sixth phase of strategic research cooperation agreement this week. The partnership aims to further advance the translation of fundamental research into new drug development across key therapeutic areas including oncology, cardiovascular & renal diseases, neurology & rare diseases, and immunology. The collaboration will also accelerate cutting-edge scientific progress throughout the pharmaceutical innovation value chain.
Collaboration Framework
Under the agreement, Bayer will continue funding joint research projects over the next three years and provide awards to Tsinghua scientists who make outstanding contributions in life sciences and pharmaceutical innovation. This initiative aims to deepen ongoing academic exchanges and discussions between both parties.
Partnership History
The partnership between Bayer and Tsinghua University dates back to 2009. Over the course of their 16-year cooperation, the two institutions have jointly conducted 75 collaborative research projects.-Fineline Info & Tech